2022
Karo Pharma Aktiebolag’s application for de-listing has been approved
Karo Pharma Aktiebolag’s (“Karo Pharma” or the “Company”) application for de-listing has now been approved by Nasdaq. The last day…
Karo Pharma Aktiebolag applies for de-listing
The Board of Directors of Karo Pharma Aktiebolag (“Karo Pharma” or the “Company”) has resolved to apply for de-listing of…
Karo Intressenter AB initiates compulsory redemption
On 16 August 2022, Karo Intressenter AB[1] (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo Pharma…
Karo Pharma Aktiebolag comments on the public offer from Karo Intressenter AB and obtains a fairness opinion
Background On 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo…
Comment from Karo Pharma Aktiebolag’s board of directors regarding the public offer from Karo Intressenter AB
Today, on 16 August 2022, Karo Intressenter AB1 (“Karo Intressenter”) announced a public cash offer to the shareholders in Karo…
Interim report H1 2022
January – June · Revenues amounted to MSEK 1 965.3 (1 460.9), corresponding to an increase of +35% for the…
Karo Pharma’s rights issue fully subscribed
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South…
Karo Pharma publishes the 2021 annual report
Today, on 12 April 2022, Karo Pharma is publishing its annual report for 2021 on the company’s website, www.karohealthcare.com. For…
Karo Pharma completes the acquisition of the E45® brand from Reckitt
Karo Pharma Aktiebolag (“Karo”) has today completed the previously announced acquisition of the skin health brand, E45®, from Reckitt for…